Author:
Sharma Sanjay,Rangarajan Ravi Velamoor
Abstract
Diabetes is a chronic metabolic condition that has far-reaching consequences for human health. If there is no appropriate therapeutic treatment, diabetic peripheral neuropathy might lead to foot ulceration and limb amputation. Conventional pharmacological therapy have weak anti-DPN activity. By stimulating nerve regeneration, addressing underlying causes of the disorder, and alleviating symptoms, stem cell therapy for diabetic peripheral neuropathy has the potential to alter the management of this debilitating illness. One of its most significant advantages is its ability to regenerate damaged nerves, as stem cells may differentiate into a variety of cell types, including neurons and supporting cells. Preclinical and early-phase clinical research has resulted in improvements in nerve conduction, pain alleviation, and sensory function in patients with diabetic peripheral neuropathy. Stem cell therapy can be tailored to each patient's specific ailment, ensuring personalized care that improves therapeutic outcomes. Future research may uncover further benefits and applications for stem cell treatment, such as refining stem cell source selection, experimenting with novel delivery systems, and capitalizing on tissue engineering advances. Combining stem cell therapy with gene editing or bioengineering procedures may improve regenerative potential in the treatment of diabetic peripheral neuropathy. To completely reap the benefits of stem cell therapy in diabetic peripheral neuropathy, obstacles must be overcome and treatment procedures must be improved. Stem cell therapy has the potential to revolutionize the treatment of diabetic peripheral neuropathy by encouraging nerve regeneration, and symptom relief. The present review discusses the noteworthy developments in various regenerative therapies for diabetic peripheral neuropathy.
Publisher
European Open Science Publishing
Reference88 articles.
1. Marchettini P, Lacerenza M, Mauri E, Marangoni C. Painful peripheral neuropathies. Curr Neuropharmacol. 2006 Jul;4(3):175–81. doi: 10.2174/157015906778019536. PMID: 18615140; PMCID: PMC2430688.
2. Hansson PT, Lacerenza M, Marchetti P. Aspects of clinical and experimental neuropathic pain: the clinical perspective. In Neuropathic Pain: Pathophysiology and Treatment. Progress in Pain Research and Management. Hansson PT, Fields HL, Hill RG, Marchettini P, Eds. vol. 21. Seattle: IASP Press, 2001, pp. 1–18.
3. Max MB. Clarifying the definition of neuropathic pain. Pain. 2002;96:406–7.
4. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019 Jun 13;5(1):42. doi: 10.1038/s41572-019-0097-9. PMID: 31197183; PMCID: PMC7096070.
5. Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J. 2006 Feb;82(964):95–100. doi: 10.1136/pgmj.2005.036137. PMID: 16461471; PMCID: PMC2596705.